Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.29 USD | +0.78% | 0.00% | -18.87% |
May. 24 | Cyclo Therapeutics Files $100 Million Mixed Shelf | MT |
May. 01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
Financials (USD)
Sales 2024 * | 1.2M | Sales 2025 * | 2.11M | Capitalization | 36.76M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -23M | EV / Sales 2024 * | 30.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 17.4 x |
P/E ratio 2024 * |
-1.73
x | P/E ratio 2025 * |
-2.13
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.38% |
1 week | -1.16% | ||
Current month | -12.67% | ||
1 month | -13.27% | ||
3 months | -20.31% | ||
6 months | -6.93% | ||
Current year | -19.81% |
Managers | Title | Age | Since |
---|---|---|---|
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Joshua Fine
DFI | Director of Finance/CFO | 42 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
William Shanahan
BRD | Director/Board Member | 84 | 16-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 1.29 | +0.78% | 23,879 |
24-05-28 | 1.28 | -5.19% | 12,537 |
24-05-24 | 1.35 | +3.85% | 28,979 |
24-05-23 | 1.3 | +0.78% | 53,703 |
24-05-22 | 1.29 | -5.15% | 23,999 |
Delayed Quote Nasdaq, May 29, 2024 at 01:57 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.81% | 36.76M | |
+39.05% | 727B | |
+30.57% | 592B | |
-7.74% | 347B | |
+15.60% | 319B | |
-0.46% | 274B | |
+12.55% | 238B | |
+6.65% | 204B | |
-6.09% | 203B | |
-3.00% | 160B |
- Stock Market
- Equities
- CYTH Stock